Treatment for Pancolitis

Initial Assessment and Diagnosis

The European Crohn’s and Colitis Organisation recommends confirming diagnosis and disease activity through sigmoidoscopy and excluding infection before initiating treatment 1, 3
Disease severity should be evaluated using clinical activity indices (such as Truelove & Witts' or Simple Clinical Colitis indices) to determine the appropriate management approach 1, 3
The American Gastroenterological Association suggests assessing for comorbidities through laboratory investigations including complete blood count, serum albumin, ferritin, C-reactive protein, liver enzymes, and renal function 5
Stool should be tested for Clostridium difficile and other enteric pathogens 5, 6

For mild to moderate pancolitis, the American College of Gastroenterology recommends oral aminosalicylates (mesalazine 2-4 g daily or balsalazide 6.75 g daily) as first-line therapy 1, 2, 3, 4
If there is an inadequate response to aminosalicylates, the European Crohn’s and Colitis Organisation suggests oral prednisolone 40 mg daily 1, 3
The American Gastroenterological Association recommends tapering prednisolone gradually over 8 weeks according to response 1, 3
Topical agents (such as mesalazine or steroids) may be added for troublesome rectal symptoms 1, 3

The American Gastroenterological Association suggests preferring immunomodulatory treatments with lower overall infection or malignancy risk in elderly patients 5
The European Crohn’s and Colitis Organisation recommends avoiding long-term steroid treatment and preferring nonsystemic corticosteroids when possible 5
The American College of Gastroenterology suggests balancing the convenience of oral thiopurine therapy against the slower onset of action and increased risk of nonmelanoma skin cancers and lymphoma in elderly patients 5, 7
A multidisciplinary approach should be engaged to manage care and monitor for drug interactions 5, 7

The European Crohn’s and Colitis Organisation recommends that long-term steroid treatment is undesirable 1, 3
For steroid-dependent disease, the American College of Gastroenterology suggests considering azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day 1, 3

The European Crohn’s and Colitis Organisation notes that elderly patients have a higher risk of adverse outcomes with severe disease 6
The American Gastroenterological Association recommends optimizing comorbidities to minimize risks associated with IBD treatment 5, 7
The American College of Gastroenterology suggests ensuring appropriate vaccination schedules are followed, especially before starting immunosuppression 7